Research ArticleClinical Studies
Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study
TAKAFUMI NAKANO, RYUJI YASUMATSU, KAZUKI HASHIMOTO, RYOSUKE KUGA, TAKAHIRO HONGO, HIDETAKA YAMAMOTO, MIOKO MATSUO, TAKAHIRO WAKASAKI, RINA JIROMARU, TOMOMI MANAKO, SATOSHI TOH, MUNEYUKI MASUDA, MORIYASU YAMAUCHI, YUICHIRO KURATOMI, MASAHIKO TAURA, TORANOSHIN TAKEUCHI and TAKASHI NAKAGAWA
Anticancer Research July 2022, 42 (7) 3653-3664; DOI: https://doi.org/10.21873/anticanres.15854
TAKAFUMI NAKANO
1Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;
2Department of Head and Neck Surgery, National Kyushu Cancer Center, Fukuoka, Japan;
RYUJI YASUMATSU
1Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;
KAZUKI HASHIMOTO
1Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;
RYOSUKE KUGA
1Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;
TAKAHIRO HONGO
1Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;
HIDETAKA YAMAMOTO
3Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;
MIOKO MATSUO
1Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;
TAKAHIRO WAKASAKI
1Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;
RINA JIROMARU
1Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;
TOMOMI MANAKO
1Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;
SATOSHI TOH
2Department of Head and Neck Surgery, National Kyushu Cancer Center, Fukuoka, Japan;
MUNEYUKI MASUDA
2Department of Head and Neck Surgery, National Kyushu Cancer Center, Fukuoka, Japan;
MORIYASU YAMAUCHI
4Department of Otolaryngology – Head & Neck Surgery, Saga University Faculty of Medicine, Saga, Japan;
YUICHIRO KURATOMI
4Department of Otolaryngology – Head & Neck Surgery, Saga University Faculty of Medicine, Saga, Japan;
MASAHIKO TAURA
5Department of Otolaryngology Fukuoka University School of Medicine, Fukuoka, Japan;
TORANOSHIN TAKEUCHI
6Department of Otorhinolaryngology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan
TAKASHI NAKAGAWA
1Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
patientACCESS
patientACCESS - Patients desiring access to articles
In this issue
Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study
TAKAFUMI NAKANO, RYUJI YASUMATSU, KAZUKI HASHIMOTO, RYOSUKE KUGA, TAKAHIRO HONGO, HIDETAKA YAMAMOTO, MIOKO MATSUO, TAKAHIRO WAKASAKI, RINA JIROMARU, TOMOMI MANAKO, SATOSHI TOH, MUNEYUKI MASUDA, MORIYASU YAMAUCHI, YUICHIRO KURATOMI, MASAHIKO TAURA, TORANOSHIN TAKEUCHI, TAKASHI NAKAGAWA
Anticancer Research Jul 2022, 42 (7) 3653-3664; DOI: 10.21873/anticanres.15854
Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study
TAKAFUMI NAKANO, RYUJI YASUMATSU, KAZUKI HASHIMOTO, RYOSUKE KUGA, TAKAHIRO HONGO, HIDETAKA YAMAMOTO, MIOKO MATSUO, TAKAHIRO WAKASAKI, RINA JIROMARU, TOMOMI MANAKO, SATOSHI TOH, MUNEYUKI MASUDA, MORIYASU YAMAUCHI, YUICHIRO KURATOMI, MASAHIKO TAURA, TORANOSHIN TAKEUCHI, TAKASHI NAKAGAWA
Anticancer Research Jul 2022, 42 (7) 3653-3664; DOI: 10.21873/anticanres.15854
Jump to section
Related Articles
- No related articles found.
Cited By...
- The UK Divide: Does having a Pembrolizumab-Chemotherapy option in head and neck cancer matter? Real-world experience of first-line palliative pembrolizumab monotherapy and pembrolizumab-chemotherapy combination in Scotland
- Pembrolizumab Monotherapy Versus Pembrolizumab Plus Chemotherapy in Patients With Head and Neck Squamous Cell Carcinoma
- Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer